GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Guardant Health Unveils Enhanced Guardant360 TissueNext Test, Expanding Biomarker Detection to Nearly 500 for Advanced Cancer Treatment Options

NextEdge Admin

04 Jun 2024

2 min 51 sec

Guardant Health, Inc. (NASDAQ: GH), a prominent figure in precision oncology, has unveiled an upgraded version of its Guardant360 TissueNext test, significantly broadening its gene identification capabilities within tumor tissue samples to encompass 498 genes. These genes, serving as cancer biomarkers, empower oncologists to pinpoint targeted therapies or treatment approaches most suitable for patients grappling with advanced cancer. Alongside panel expansion, Guardant has streamlined the operational workflow of the test, promising a swifter turnaround time.

This enhanced Guardant360 TissueNext test will now extend coverage to Medicare fee-for-service patients diagnosed with advanced solid tumor cancers as an independent service, aligning with the coverage guidelines stipulated by Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX®).

Guardant Health’s Chairman and co-CEO, Helmy Eltouky, emphasized the significance of this launch in advancing their mission to combat cancer using data-driven strategies. With an increased scope of gene coverage, the upgraded test aims to furnish oncologists with more comprehensive insights, facilitating better-informed decisions regarding optimal treatment strategies for patients facing advanced cancer, thereby potentially enhancing treatment outcomes.

Guardant360 TissueNext operates by identifying clinically relevant actionable biomarkers in tumor tissue, aiding oncologists in identifying individuals with advanced cancer who may benefit from treatment guided by biomarker analysis. Results are typically delivered in less than two weeks.

Originally gaining Medicare coverage in March 2022, Guardant360 TissueNext forms a pivotal component of Guardant’s comprehensive range of genomic profiling tests, encompassing both blood- and tissue-based analyses. It complements Guardant360 CDx, the FDA-approved liquid biopsy test for comprehensive genomic profiling of solid tumors. This tissue-based test can be ordered independently or in conjunction with Guardant360 CDx to support guideline-endorsed liquid and tissue genomic profiling testing for advanced breast and lung cancer.